Showing posts with label cancer. Show all posts
Showing posts with label cancer. Show all posts

Wednesday, June 11, 2014

El 'Proyecto Lydia' contra el cáncer infantil estrena video miércoles 11 junio 2014 - tel Spain 902 88 88 67 • 911 16 13 12

Camino de Santiago - Proyecto Lydia Fundación Cris ...

www.anisalud.com/.../camino-de-santiago-proyecto-ly...Translate this page
Camino de Santiago - Proyecto Lydia Fundación Cris Contra el Cáncer. Lunes, 16 de Junio de 2014 (Todo el día). Fundación CRIS, Fundación de Investigación ...

el proyecto Lydia - Cris contra el cancer

www.criscancer.org › InicioSala de prensaTranslate this page
LA FUNDACIÓN CRIS CONTRA EL CÁNCER PONE EN MARCHA EL PROYECTO LYDIA Miércoles 12 de Febrero de 2014. Los padres de Lydia, en memoria ...
  1. Europa Press ‎- 13 minutes ago
    La Fundación Telefónica ha presentado este miércoles un vídeo musical de lucha contra el cáncer infantil enmarcado en el 'Proyecto Lydia', ...

Saturday, December 4, 2010

4 years ago today I finished my radio therapy treatment

Parcialmente despejado
Alta: 12° Baja: 5°
@
Cortijo Milenium El Brosque Villanueva del Rosario
Have a great day :D

so will publish for others this information in the hope that it will help some
Remember always keep on top of your health

Breakthrough Prostate Cancer Treatments

Johns Hopkins Prostate Bulletin

Dear Health Alert Reader,

Your health and the health of your loved ones is the foremost priority of the Johns Hopkins Prostate Bulletin editorial advisory board. If you, or someone you love, has prostate disease you need the most current, reliable information you can get so you can make the best informed decisions about your future.That's why we've taken the liberty of reserving five FREE Prostate Health reports in your name:

· FREE Special Report #1: BPH: Reviewing the Options.
A must-read report on treatment options for benign prostate enlargement, with an emphasis on minimally-invasive techniques for treatment of this common disorder in men.

· FREE Special Report #2: Diet and Prostate Health.
Researchers now think up to 90% of all prostate cancers have dietary links. Our Special Report includes specific nutritional guidelines for preventing -- and coping with -- prostate disorders.

· FREE Special Report #3: Treating Overactive Bladder.
An in-depth look at current options for treating OAB -- including a close-up look at a new generation of medications that have fewer side effects than more commonly prescribed drugs.

· FREE Special Report #4: Chronic Prostatitis: New Research, Renewed Hope.
If you're one of the millions of American men who suffer from this frustrating condition, don't despair. Breakthrough research studies are pointing the way to important new therapies you need to know about.

· FREE Special Report #5: The Radical Prostatectomy.
One of the most authoritative reports on the subject available, written by Jacek L. Mostwin, M.D., D. Phil. (Oxon), Professor of Urology at Johns Hopkins, is head of the Division of Reconstructive and Neurological Urology. Essential reading for anyone facing the prospect of surgery or its after effects.

All five are yours to keep with our compliments, as your introduction to one of the most valuable health resources you'll ever benefit from:

The Johns Hopkins Prostate Bulletin is the most comprehensive up-to-the-minute round-up of prostate care advances, new research findings, and clinical trials ever made available to medical consumers.

The Johns Hopkins Prostate Bulletin works with doctors and professors of urology at one of the nation's foremost urological center, we are constantly impressed by the wealth of new therapies, important breakthroughs and newly-discovered preventive measures available to men at high risk for prostate problems, or undergoing treatment for them.

Yet for the average medical consumer, the information has simply been inaccessible -- hidden in obscure medical journals or buried in miniscule articles in the back of the daily newspaper. Even many physicians may not have ready access to up-to-the-minute research in this highly specialized field.

As the nation's leading center for prostate care and research, Johns Hopkins' James Buchanan Brady Urological Institute is in a unique position to evaluate and disseminate the very latest information concerning advances in prostate treatment. Now, Dr. Jacek Mostwin is leading a team of world-class prostate specialists as chief medical editor of a remarkable publication created for that precise purpose.

The Johns Hopkins Prostate Bulletin has one simple mission, one clear focus: to provide those facing prostate health challenges with the kind of authoritative, leading-edge information they need to take charge of their medical care -- intelligently and effectively.

The Johns Hopkins Prostate Bulletin brings you eye-opening reports about new therapeutic avenues. . . advance news of clinical trials in which you can participate. . . detailed answers to subscribers' most pressing questions and concerns. . . revealing research findings about nutrition, supplementation, lifestyle influences and diagnostic tools. . . and the latest news from urological and cancer conferences around the world. All with a single relentless focus on prostate issues and the preservation of your health and quality of life, and without mysterious medical jargon -- so you can clearly understand what the advances mean to you.

This can literally be life-changing information -- especially if you fall within the prostate high-risk target zone, which includes men over 40, African-Americans, and any male with a family history of prostate problems. In recent issues, The Prostate Bulletin subscribers have learned about:

· Exciting lab tests of a powerful molecule, developed by a researcher at Yale, that appears to attack prostate cancer cells in mice and wipe them out. Human clinical trials are expected to be underway shortly. The Prostate Bulletin will provide contacts for these trials as soon as they are announced.

· Why experts now estimate that up to 90 percent of cancers of the prostate may have a dietary link.

· New evidence that the progression of prostate cancer may actually be slowed by dietary changes. One study published in the Journal of Urology found that tumor cells from men taking flaxseed in combination with a lowfat diet appeared to be growing more slowly and dying more quickly than those of the control group.

· Two types of foods that should be included plentifully in the diet of anyone at risk for prostate problems -- or experiencing them.

· Expert guidance for dealing with erectile dysfunction and restoring intimacy and sexual satisfaction after prostate surgery.

· Important prostate issues to consider if you're contemplating testosterone replacement therapy. The good news: most urologists now recommend replacement therapy for men with low testosterone levels -- provided careful follow-up examinations are maintained.

· Must-read comparison of the new laparoscopic prostatectomy with the traditional radical prostatectomy. The latest reports from the annual meeting of the American Urological Association offer important insights about the relative merits of both approaches for curing prostate cancer and maintaining quality of life.

· Why a new use of an oral hormonal medication may represent an important breakthrough in prostate cancer treatment.

· How a team of scientists and physicians is zeroing in on an improved Prostate Specific Antigen (PSA) test -- one which will reduce false positive readings and provide greater accuracy in predicting which men have PSA elevations due to benign prostate enlargement, and which are due to prostate cancer. The Prostate Bulletin readers will be kept apprised of their success as the data is reported.

· Five questions you should ask your surgeon if you are facing a radical prostatectomy. If he answers negatively to any one of them consider seeking treatment elsewhere. Question #1: does he know and use the nerve-sparing techniques in performing prostate surgery?

· Overactive bladder? You're not alone -- an estimated 17 million Americans, most under the age of 65, are affected by OAB. Your symptoms could be caused by one of the 12 trigger foods we reported on in our latest in-depth report on treating overactive bladder.

· The biggest mistake physicians make in prescribing drugs for prostate enlargement. Important reading for anyone taking Hytrin, Cardura, Flomax or Minipress.

· The pros and cons of medications, minimally-invasive therapies, and surgical alternatives in treating benign prostatic hyperplasia (BPH) -- the most common benign tumor found in men. Dr. Alan W. Partin, M.D., Ph.D, and Distinguished Professor of Urologic Oncology at the Johns Hopkins University School of Medicine reviews treatment options in our in-depth report on BPH.

· Where to find national listings of clinical trials of new therapies for BPH and prostate cancer -- and how you can apply to take part in them.

The most important publication you'll ever read --
yet your subscription is entirely risk-FREE.

If you or a loved one has reason to be concerned about prostate health, The Johns Hopkins Prostate Bulletin is the most essential resource you'll ever subscribe to -- even if you've never been diagnosed with a health-threatening prostate condition. The Prostate Bulletin will keep you abreast of the latest studies, therapies, and breakthroughs, alert you to clinical trials in which you can participate, and bring you the latest news from urological and cancer conferences around the world. All without medical jargon -- so you can clearly understand what the advances mean to you.

This can literally be life-saving information. . . yet your subscription to The Prostate Bulletin is entirely risk-FREE. The subscription cost is just $149 for four quarterly issues. . . a savings of $46 off the regular subscription price. And, here's more good news: If you are dissatisfied with the Bulletin at any time, for any reason. . . simply contact us for a prompt and complete refund, no questions asked.

The five FREE Prostate Bulletin Special Reports
are yours to keep, even if you decide not to continue.

Recently, we issued five Special Reports on prostate health issues that we consider so important, we want you to have them immediately. All five will be included on a complimentary basis with your subscription -- and they're yours to keep even if you don't continue as a subscriber to the Prostate Bulletin. You'll receive Special Reports on:

· FREE Special Report #1: BPH: Reviewing the Options.
A must-read report on treatment options for benign prostate enlargement. From watchful waiting and pharmaceutical therapies, to surgical solutions, this comprehensive guide explains the alternatives and lists the pros and cons of each.

· FREE Special Report #2: Diet and Prostate Health.
Researchers now think up to 90% of all prostate cancers have dietary links. Our Special Report includes the latest dietary guidelines for preventing cancer, and possibly even slowing its growth.

· FREE Special Report #3: Treating Overactive Bladder.
An in-depth look at the complete range of current options for treating OAB -- including some your physician may not yet be familiar with.

· FREE Special Report #4: Chronic Prostatitis: New Research, Renewed Hope.
If you're one of the millions of American men who suffer from this frustrating condition, don't despair. Breakthrough research studies are pointing the way to promising new therapeutic avenues.

· FREE Special Report #5: The Radical Prostatectomy.
If you're facing prostate surgery or recovering from it, this Special Report by a leading authority in the field is must reading.

A risk-FREE opportunity
to improve your medical outlook --
and save $46!

All five Special Reports are yours to keep without risk, obligation or further commitment as a gift of good health from your friends at Johns Hopkins. We know these Special Reports will make a major difference in your prostate health outlook. But we also know that they only scratch the surface of the wealth of vital information available to you as a subscriber to The Prostate Bulletin.

Your subscription will include:

· Four quarterly issues of The Prostate Bulletin, packed with up-to-the-minute health-essential information.

· Personal Letter reviewing critical prostate developments of the past few weeks. Each issue of The Prostate Bulletin starts with Dr. Mostwin's Personal Letter -- up to 20 pages of late-breaking news and information about the very latest treatment strategies and early intervention options, plus first-hand reports from urological conferences around the world that are helping men to prolong their lives, and improve their quality of life.

· In-Depth Reports on prostate health issues ranging from treatment options and preventive measures to prostatectomy techniques and new diagnostic tools. Each report is authored by a recognized expert on its topic -- including such medical authorities as Dr. H. Logan Holtgrewe, M.D., former president of the American Urological Association. . . Dr. Alan W. Partin, M.D., Ph.D., Urologist-in-Chief of the James Buchanan Brady Urological Institute and editor-in-chief of Urology. . . Dr. Patrick C. Walsh, M.D., former Director of the James Buchanan Brady Urological Institute. . . and literally dozens more who are at the forefront of prostate research and treatment.

· Participation in our Grand Rounds forum -- in which readers have the opportunity to pose specific prostate health questions to Johns Hopkins specialists. While we can't guarantee that every single question will be answered, typical issues include as many as ten to twelve pages' worth of readers' questions and expert answers.

· 5 FREE Special Reports on important prostate issues, yours to keep even if you decide not to continue with your subscription.

When it comes to prostate care, information is the best medicine.
To order your Risk-Free copy of the Prostate Bulletin. . . and get your 5 FREE Special Reports. . . just click below now:

ORDER TODAY!


Thursday, July 29, 2010

Goldbug100 - AIDA Pharmaceuticals, Inc. (AIDA.PK)

31 Dingjiang Road
Jianggan District
Hangzhou   ZHJ   310016
P: +86571.85802712
IDA Pharmaceuticals, Inc., incorporated in December 18, 2002, and located in Hangzhou, the People’s Republic of China, operates through its subsidiaries, which include Earjoy Group Limited (Earjoy), Hangzhou Aida Pharmaceutical Co., Ltd (Hangzhou Aida), Hangzhou Boda Medical Research and Development Co., Ltd. (Boda), Hainan Aike Pharmaceutical Co., Ltd. (Aike), Changzhou Fangyuan Pharmaceutical Co., Ltd. (Fangyuan) and Shanghai Qiaer Bio-technology Co., Ltd (Qiaer). Earjoy is an investment holding company. Hangzhou Aida is a pharmaceutical company engaged in the development, manufacture, marketing, licensing, and distribution of pharmaceutical products primarily in mainland China. Hangzhou Aida has a total of nine production lines for the manufacture of antibiotics, cardiovascular and anti-tumor drugs in various forms, including injectable powder, injectable liquid, capsules, tablets and ointments. Hangzhou Aida’s primary product is the injectable powder form of Etimicin Sulfate.

Boda is a wholly owned subsidiary of Hangzhou Aida and engages itself in the research and development of new drugs. Aike specializes in the production of transfusion type of Etimicin AiYi. Fangyuan is a 66%-owned subsidiary of Hangzhou Aida. Fangyuan is a supplier of raw material for Etimicin and is also a producer of the liquid type of Etimicin ChuangCheng. The key product of Qiaer is Apoptotic Factor (rh-Apo2l), a potential biopharmaceutical therapy with genetic engineering techniques used for cancers.

On March 26, 2008, Hangzhou Aida signed a purchase agreement with Jin’ou Medicine Co., Ltd to acquire a 43% equity interest in Jiangsu Institute of Microbiology Co., Ltd. On March 26, 2008, Fangyuan signed a purchase agreement with Jiangyin Hi-tech Group to acquire 55% interest in Jiangsu Institute of Microbiology Co., Ltd. 

Etimicin Sulfate is an amino glycoside family of antibiotics. It is suitable for the treatment of various inflammations, including respiratory infection, such as acute bronchitis, acute onset of chronic bronchitis and pulmonary infections; kidney and urinogenital infection, such as acute pyelonephritis or acute onset of chronic cystitis; soft skin tissue infection, and trauma and operations (before and after) preventive uses. 

The products being developed by AIDA Pharmaceuticals include rh-Apo2l, Vasostatin –Apo2L, Prodigiosin, Anti-CD86 Monoclonal Antibody and Anti-CTLA-4 Monoclonal Antibody. Rh-Apo2l is being evaluated in a Phase II trial which started in February 2007. Vasostatin –Apo2L is a recombinant fusion protein that is being tested as a potential cancer drug. It integrates the function of extracted fragment of Vasostatin, an inhibitor of angiogenesis and tumor growth, with the function of rh-Apo2l which induces the apoptosis of cancer cells. Prodigiosin, a naturally occurring red pigment, is in pre-clinical trials for the treatment of pancreatic cancer. 

Certain immunity diseases activate T-cells (a type of white blood cell), causing them to unnecessarily attack healthy tissue. Anti-CD86 Monoclonal Antibody inhibits T-cells from harming healthy tissue. In the case of certain cancers, tumors over-express self-proteins, essentially hiding the tumor from the immune system. The Company is in the development stages of an Anti-CTLA-4 Monoclonal Antibody, which may relieve the inhibition of T-cells allowing them to identify the over-expressed proteins and in turn naturally attacking cancer cells without harming healthy tissues.

AIDA Pharmaceuticals's main production facilities are located in Hangzhou in the Zhejiang Province, in Changzhou in the Jiangsu Province and in Haikou in the Hainan Province. The raw materials and supplies for manufacturing at the plants are sourced from suppliers in China. The supplier for Etimicin Sulfate base aside from Fangyuan is Shanhe Pharmaceuticals Co., Ltd. in Wuxi, Jiangsu Province.

In the Goldbug 100 portolio - the Fund Manager feels that a HKSE listing would be better for this company than the current Pink Sheet one, but of course the listing costs may prohibit this. Price paid $1.15 at the peak of the bull market in 2008. The fund does not like the reporting of Pink Sheet shares. AIM on the London Stock Exchange shows potential investors far more details.
.
Important information for the investor - Price earning ratio / assets per share and of course future dividend policy etc. The fund in view of the lack of reporting of Pink Sheet shares really is reluctant to "average out" on it´s holdings in PS companies which are more suitable to "day traders" and are the fodder of "Pump and dump" internet web sites who paint a rosy picture of their client´s prospects

Affordable China Tours package, Book now and save 30-70%-ChinaTravelDepot.com

Tuesday, January 22, 2008

Spanish Property for Sale - Reason Cancer

Location - Near Granada
Having had cancer myself I am posting the photograph of the property that is for sale - Full details
This patient is terminal so anyone genuinely interested please e-mail me as quickly as possible. I will send you the photos and room dimensions and if you are interested in viewing a friend of the owner has the keys and will show you the property. Alternatively you can phone me 00 34 952031010 (John Nichols)
PRICE - 157.500 euros

Tuesday, May 29, 2007

Prostate Cancer (personal)

Yesterday I drove down to the University Hospital of Malaga Carlos Haya for my appointment with my oncologist. He assured me that with an original PSA value under 10 that the cancer had not spread anywhere else, but having seen my sister die a few years earlier from metastasis (originating from the Esophagus) and a friend dying when I was a just starting my radio therapy treatment it is obviously difficult not to worry about the spread of the disease when you have symptoms that could be cancer.

Cancer gives you no symptoms or signs that exclusively indicate the disease. Every complaint for cancer can explain a harmless condition as well. If you have symptoms, however, you should see a doctor for further evaluation. Some common symptoms are : Click this link

A couple of weeks ago visiting friends asked me about my attitude and I said cautious. I did not want to be positive to the point of being over optimistic. I recognize that I could be on borrowed time and that this has been a "wake up call".

(In the United States, cancer of the prostate is a common malignant cancer in men, second only to lung cancer. About 200,000 new cases are diagnosed each year, and about 30,000 men die of the disease each year).

I have never smoked and maybe had a glass of wine a day, but now I hardly drink and am eating more healthily. I appreciate being alive and really would love to see the trees that I have lovingly grow much larger. There is a particular plant that I have vowed that I will plant in my garden, one for every further year that I am allowed to enjoy here "Cotinus Coggyria (Royal Purple)". On reflection maybe I should have written a blog during my 40 sessions of treatment? The treatment was not painful, but the after effects have only just receded, the treatment having finished on 5 December 2006.

The staff at the University Hospital of Malaga Carlos Haya were marvelous, as were my fellow patients, so much so that tears came to my eyes as I drove away after my last treatment as I listened to Nelly Furtado´s - In Gods Hands, - Wait for You and All Good Things (come to an end). They could not have given me a better Christmas present and I am so grateful to the Spanish Social Security. My treatment, as promised had started within 2 months of being diagnosed, ok one day earlier and since that date I have read that they are going to bring this down to one month in the future in their fight against this disease.

Whilst undergoing treatment I did quite a bit of research and decided to publish a page on the pomegranate and its use against prostate cancer.

Yesterday my oncologist was pleased with my progress the PSA having come down to 0,17% from 0,21% three months earlier so my next control will be in 6 months time. Obviously there will be a control for the next four and a half years.


Did I have any prostate problem symptoms? No it was just a regular annual blood test and keeping on top of my health that brought the problem to light. The highest PSA in 2005 was 8.4% but the tumor was not malignant.

With 3 months medication it had been brought down to 4% but after 3 months without medication it had risen to 6.3% by July 2006 - T2a and a Gleeson Value of 5 were the results of a biopsy. All were surprised by these results known in August 2006.

I quickly made the decision to have radio therapy and hormone treatment rather than the operation. I appreciate life far more today.

links

My page on Prostate Cancer
Cancer Symptoms Glossary of Medical Terms
Prostate Cancer Overview
More links on University Hospital of Malaga Carlos Haya